Revolution Medicines Closes $1.65B Equity Offering, Secures $500M Convertible Notes for $2.14B Total Capital Raise

summarizeSummary

Revolution Medicines, Inc. announced the closing of its upsized $1.65 billion common stock offering and provided an update on its $500 million convertible senior notes offering, bringing the total capital raise to approximately $2.14 billion.

check_boxKey Events

• Equity Offering Finalized and Closed

  The company closed its common stock offering on April 16, 2026, issuing 12,147,887 shares (including the full exercise of underwriters' option) at $142.00 per share, generating approximately $1.65 billion in net proceeds.

• Convertible Note Offering Details Confirmed

  A concurrent offering of $500 million aggregate principal amount of 0.50% Convertible Senior Notes due 2033 was agreed upon, with expected net proceeds of approximately $486.8 million and an anticipated closing date of April 17, 2026.

• Significant Capital Infusion for Pipeline

  The combined offerings are expected to raise approximately $2.14 billion in total net proceeds, which will be used for general corporate purposes, including funding research and development, and potential commercialization of product candidates.

• Strategic Timing Near 52-Week Highs

  The capital raise was strategically timed following positive clinical trial results announced on April 13, 2026, and executed while the stock is trading near its 52-week high, demonstrating an opportunistic approach to funding growth.

auto_awesomeAnalysis

Revolution Medicines, Inc. has successfully closed its upsized common stock offering, raising approximately $1.65 billion in net proceeds. Concurrently, the company entered into an agreement for a $500 million convertible senior notes offering, expected to close on April 17, 2026, bringing the total capital secured from these concurrent offerings to approximately $2.14 billion. This substantial capital infusion follows closely on the heels of highly positive clinical trial results announced on April 13, 2026, positioning the company to aggressively fund its research and development pipeline and potential commercialization efforts. The equity offering was priced at $142.00 per share, a slight discount to the last reported sale price of $147.01 on April 14, 2026, but the upsized nature and timing near the company's 52-week high indicate strong market demand and a strategic move to capitalize on favorable conditions. Officers and directors are subject to a 45-day lock-up period, which is standard for such offerings.